Eurofarma and NLS-1Pharma establish a partnership for the development and commercialization of a novel treatment for ADHD in Latin America
Published in: March 18, 2019
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, March 2019 – Eurofarma, a 100% Brazilian pharmaceutical company with presence in 20 Latin American countries, announces an agreement with NLS-1 Pharma, a Swiss biotech company, for an exclusive license for an innovative treatment against Attention Deficit Hyperactivity Disorder (ADHD). The treatment is currently in clinical development phase, expected to reach the market in 2023.
ADHD usually manifests in childhood and approximately 60% of those who suffer from it carry the condition for the entire life2. It is a neurobiological disorder, of genetic causes, characterized by symptoms such as inattention, restlessness and impulsivity2. In the United States, the latest health survey conducted by the 2011 National Survey of Children's Health estimated a prevalence of 11% among children aged 4-17 years3. In Brazil, it is estimated that only 10% of children diagnosed, due to parents' fear of using controlled medications, receive the correct treatment1, which must be composed by medical monitoring, psychological, educational and family support. Currently, medications available in the market are amphetamine-based drugs and stimulants.
With the objective of offering an alternative option to doctors and patients, NLS-1 Pharma is working on the reformulation and repurposing of a non-amphetamine molecule, mazindol CR, for the treatment of ADHD. Preliminary data in children as well as adults showed promising results, with an efficacy profile comparable to current first line therapies, and a better safety profile in terms of drug abuse and dependence. Phase 3 clinical studies are expected to confirm these results to date.
The partnership reinforces Eurofarma's commitment to seek innovative treatments for the Central Nervous System (CNS) therapeutic area, one of the core focus areas of the company. "Investing in innovative drugs is part of the company's strategy. And offering a new treatment option for the medical class, which brings greater peace of mind for parents and more quality of life for the ADHD people is a source of great pride," says Martha Penna, vice president of Innovation at Eurofarma.
For NLS-1 Pharma, the expectations of reaching the Latin American market are very high. “We are very excited to start, what we believe will be, a longlasting and successful partnership with one of the most ambitious and fasted growing pharma companies in Latinamerica“ stated Alex Zwyer, CEO of NLS-1 Pharma.
1 - Brazilian Association of Attention Deficit (BAAD) Treatment. Available at https://tdah.org.br/tratamento/ (Accessed on January 23, 2019)
2 - Brazilian Association of Attention Deficit (ABDA). What is ADHD? Available at https://tdah.org.br/sobre-tdah/o-que-e-tdah/ (Accessed on January 23, 2019)
3 - Data Resource Center for Child & Adolescent Health. Available at http://www.childhealthdata.org/learn-about-the-nsch/NSCH (Accessed on January, 23 2019)
About the Eurofarma Group
With 47 years of existence, Eurofarma is the first Brazilian pharmaceutical multinational company. With 100% national capital, it is recognized by the medical community and society for promoting access to health and quality of life with a fair price, quality and innovative treatments.
With presence in 20 countries, it operates in the areas of Medical Prescription, OTC, Generic, Hospital, Bids, Oncology, Veterinary and Services for third parties’ segments. In Brazil, the portfolio is composed by more than 330 brands, with around 1000 presentations covering 28 medical specialties and 48 therapeutic classes.
In Brazil, Eurofarma is ranked 2nd in medical prescriptions and the 3rd in the generic segment.
For more information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br
About NLS-1 Pharma
NLS-1Pharma is a privately owned, Swiss-based biotech focusing on the development of first-in-class treatments for ADHD, sleep disorders, cognitive impairment and other neurological disorders that remain largely - and for which unmet medical needs are significant. NLS-1 Pharma has built a large portfolio of promising clinical-stage medicines being developed by an experienced team of proven experts in ADHD and sleep- related disorders and working closely with key opinion leaders.
Press Information:
Eurofarma Laboratories
André Pascowitch - +55 11 5090-8600 ext.8369 - andre@gaspar.com.br
Guilherme Gaspar + 55 11 3065-3045 – guilherme@gaspar.com.br
ADHD usually manifests in childhood and approximately 60% of those who suffer from it carry the condition for the entire life2. It is a neurobiological disorder, of genetic causes, characterized by symptoms such as inattention, restlessness and impulsivity2. In the United States, the latest health survey conducted by the 2011 National Survey of Children's Health estimated a prevalence of 11% among children aged 4-17 years3. In Brazil, it is estimated that only 10% of children diagnosed, due to parents' fear of using controlled medications, receive the correct treatment1, which must be composed by medical monitoring, psychological, educational and family support. Currently, medications available in the market are amphetamine-based drugs and stimulants.
With the objective of offering an alternative option to doctors and patients, NLS-1 Pharma is working on the reformulation and repurposing of a non-amphetamine molecule, mazindol CR, for the treatment of ADHD. Preliminary data in children as well as adults showed promising results, with an efficacy profile comparable to current first line therapies, and a better safety profile in terms of drug abuse and dependence. Phase 3 clinical studies are expected to confirm these results to date.
The partnership reinforces Eurofarma's commitment to seek innovative treatments for the Central Nervous System (CNS) therapeutic area, one of the core focus areas of the company. "Investing in innovative drugs is part of the company's strategy. And offering a new treatment option for the medical class, which brings greater peace of mind for parents and more quality of life for the ADHD people is a source of great pride," says Martha Penna, vice president of Innovation at Eurofarma.
For NLS-1 Pharma, the expectations of reaching the Latin American market are very high. “We are very excited to start, what we believe will be, a longlasting and successful partnership with one of the most ambitious and fasted growing pharma companies in Latinamerica“ stated Alex Zwyer, CEO of NLS-1 Pharma.
1 - Brazilian Association of Attention Deficit (BAAD) Treatment. Available at https://tdah.org.br/tratamento/ (Accessed on January 23, 2019)
2 - Brazilian Association of Attention Deficit (ABDA). What is ADHD? Available at https://tdah.org.br/sobre-tdah/o-que-e-tdah/ (Accessed on January 23, 2019)
3 - Data Resource Center for Child & Adolescent Health. Available at http://www.childhealthdata.org/learn-about-the-nsch/NSCH (Accessed on January, 23 2019)
About the Eurofarma Group
With 47 years of existence, Eurofarma is the first Brazilian pharmaceutical multinational company. With 100% national capital, it is recognized by the medical community and society for promoting access to health and quality of life with a fair price, quality and innovative treatments.
With presence in 20 countries, it operates in the areas of Medical Prescription, OTC, Generic, Hospital, Bids, Oncology, Veterinary and Services for third parties’ segments. In Brazil, the portfolio is composed by more than 330 brands, with around 1000 presentations covering 28 medical specialties and 48 therapeutic classes.
In Brazil, Eurofarma is ranked 2nd in medical prescriptions and the 3rd in the generic segment.
For more information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br
About NLS-1 Pharma
NLS-1Pharma is a privately owned, Swiss-based biotech focusing on the development of first-in-class treatments for ADHD, sleep disorders, cognitive impairment and other neurological disorders that remain largely - and for which unmet medical needs are significant. NLS-1 Pharma has built a large portfolio of promising clinical-stage medicines being developed by an experienced team of proven experts in ADHD and sleep- related disorders and working closely with key opinion leaders.
Press Information:
Eurofarma Laboratories
André Pascowitch - +55 11 5090-8600 ext.8369 - andre@gaspar.com.br
Guilherme Gaspar + 55 11 3065-3045 – guilherme@gaspar.com.br